AP NEWS

QIAGEN and Hamilton Launch New Collaboration to Improve Pre-Analytical Sample Processing for QuantiFERON-TB Gold Plus

July 30, 2018

GERMANTOWN, Md. & HILDEN, Germany, and RENO, Nev.--(BUSINESS WIRE)--Jul 30, 2018--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Hamilton Robotics, a privately held leader in automation and liquid handling technology, today announced a new collaboration to improve processing of QIAGEN’s QuantiFERON-TB Gold Plus (QFT-Plus) diagnostic test through the integration of Hamilton’s Microlab ® STAR™ automated liquid handling workstation into the QFT-Plus assay workflow. QIAGEN’s fourth-generation QuantiFERON-TB Gold Plus is the modern gold standard for latent tuberculosis (TB) detection.

QuantiFERON-TB Gold Plus offers customers the most flexible workflow among TB screening tests, including a single-tube option that enables efficient screening in large-scale programs by collecting blood samples at patient sites and transporting them to labs for processing up to 53 hours after venipuncture. Use of the Microlab STAR workstation will standardize and automate the manual steps in liquid handling for those samples, which can reduce hands-on time by 50% or more, provide greater ease of use and ensure consistency in pre-analytic methods, reducing processing errors and variability between runs.

“We are pleased to collaborate with Hamilton, a proven leader with a track record of providing best-in-class liquid handling technology solutions, to further improve the automation of our QuantiFERON-TB Gold Plus test for customers,” said Thierry Bernard, Senior Vice President, Head of the Molecular Diagnostics Business Area at QIAGEN N.V. “This integrated workflow, which has potential to be rolled out globally, should significantly improve laboratories’ economics and ease of use for the QuantiFERON-TB technology, especially in clinical markets that increasingly rely on the single-tube collection version of the test.”

Michael Mouradian, Director of Robotics at Hamilton Robotics added, “Our collaboration with QIAGEN puts the clinician and patient at center stage when it comes to tuberculosis testing. With this hands-free automated workflow, everyone can be confident that the next steps in patient care are based on highly accurate and timely results.”

Please find the full press release here

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005539/en/

CONTACT: QIAGEN

Investor Relations

John Gilardi

+49-2103-29-11711

or

Dr. Sarah Fakih

+49-2103-29-11457

e-mail:ir@QIAGEN.com

or

Hamilton Robotics

Chere Griffin

Expression Marcom

+1-908-818-9463

e-mail: CGriffin@expressionmarcom.com

or

Public Relations

Dr. Thomas Theuringer

+49-2103-29-11826

or

Robert Reitze

+49-210-29-11676

e-mail:pr@QIAGEN.com

KEYWORD: AUSTRIA UNITED STATES EUROPE NORTH AMERICA MARYLAND GERMANY NEVADA SWITZERLAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS INFECTIOUS DISEASES MEDICAL DEVICES

SOURCE: QIAGEN

Copyright Business Wire 2018.

PUB: 07/30/2018 04:06 PM/DISC: 07/30/2018 04:06 PM

http://www.businesswire.com/news/home/20180730005539/en

AP RADIO
Update hourly